Provided by Tiger Trade Technology Pte. Ltd.

Lexaria Bioscience Corp

10.35
-1.3300-11.39%
Post-market: 10.30-0.0474-0.46%19:30 EDT
Volume:61.91K
Turnover:697.22K
Market Cap:17.10M
PE:-2.01
High:12.48
Open:11.42
Low:10.35
Close:11.68
52wk High:23.25
52wk Low:4.21
Shares:1.65M
Float Shares:1.61M
Volume Ratio:0.57
T/O Rate:3.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.1429
EPS(LYR):-9.9189
ROE:-162.77%
ROA:-81.30%
PB:3.61
PE(LYR):-1.04

Loading ...

Lexaria Says DehydraTECH 3.0 Retatrutide Tablet Boosts Absorption up to 4,552% in Dog Study

Reuters
·
Aug 24

Lexaria Regains NASDAQ Bid Price Compliance, Avoids Delisting Hearing

Reuters
·
Aug 18

Lexaria Bioscience enters MTA with PegBio

TIPRANKS
·
Aug 17

Lexaria Bioscience - Mta to Investigate Co’s Dehydratech Technology with Proprietary Pegbio Molecule Under Development for Glp-1 Industry

THOMSON REUTERS
·
Aug 13

Lexaria Bioscience Corp - Enters a Material Transfer Agreement with Pegbio

THOMSON REUTERS
·
Aug 13

Lexaria Signs Material Transfer Agreement with PegBio to Test DehydraTECH with GLP-1 Molecule

Reuters
·
Aug 13

Lexaria Risks NASDAQ Delisting After Missing $1 Minimum Bid Price Rule

Reuters
·
Aug 11

Lexaria Bioscience Corp trading halted, volatility trading pause

TIPRANKS
·
Aug 03

NASDAQ Trade Halt Continues Volatility Trading Pause at 09:59 Am

Reuters
·
Aug 03

NASDAQ Trade Halt Continues Halt News Pending at 03:28 Am

Reuters
·
Aug 02

Lexaria Bioscience Corp trading halted, news pending

TIPRANKS
·
Aug 01

Lexaria Bioscience Corp - Authorizes 1-for-15 Reverse Stock Split - SEC Filing

THOMSON REUTERS
·
Jul 31

Lexaria Bioscience announces effective date for reverse stock split

TIPRANKS
·
Jul 30

Lexaria Bioscience to Execute 1-for-15 Reverse Stock Split Aug. 3

Reuters
·
Jul 30

Lexaria Bioscience Q3 EPS $(0.08) Beats $(0.09) Estimate

Benzinga Earnings
·
Jul 14

Lexaria FY26 Nine-month Net Loss Narrows to US$ 5.04 Million; Revenue Drops to US$ 20,000

Reuters
·
Jul 14

Lexaria Bioscience Corp Expected to Post a Loss of 8 Cents a Share - Earnings Preview

Reuters
·
Jul 10

Lexaria Bioscience ‘s human study GLP-1-H26-7 has begun dosing

TIPRANKS
·
Jun 25

Lexaria Begins Dosing in Five-week Oral Semaglutide Study Versus Novo’s Wegovy Tablets

Reuters
·
Jun 25

Lexaria Bioscience begins dosing in animal study GLP-1-A26-1

TIPRANKS
·
Jun 23